Long-Term Safety and Disease Control With Ruxolitinib Cream in Patients With More Severe Atopic Dermatitis: Pooled Results From Two Phase 3 Studies. J of Skin 2021, 5 (6), s66. https://doi.org/10.25251/skin.5.supp.66.